Abstract

In this study, we evaluated whether the digital program Vitadio achieves comparable results to those of an intensive in-person lifestyle intervention in obesity management. This is a 12-month prospective, randomized controlled trial. Obese patients with insulin resistance, prediabetes or type 2 diabetes were included. The intervention group (IG) used Vitadio. The control group (CG) received a series of in-person consultations. Body weight and various metabolic parameters were observed and analyzed with ANOVA. The trial is ongoing and the presented findings are preliminary. Among 100 participants (29% men; mean age, 43 years; mean BMI, 40.1 kg/m2), 78 completed 3-month follow-up, and 51 have completed the 6-month follow-up so far. Participants significantly (p < 0.01) reduced body weight at 3 months (IG: −5.9 ± 5.0%; CG: −4.2 ± 5.0%) and 6 months (IG: −6.6±6.1%; CG: −7.1 ± 7.1%), and the difference between groups was not significant. The IG achieved favorable change in body composition; significant improvement in TAG (−0.6 ± 0.9 mmol/l, p < 0.01), HDL (0.1 ± 0.1%, p < 0.05), HbA1c (−0.2 ± 0.5%, p < 0.05) and FG (−0.5 ± 1.5 mmol/l, p < 0.05); and a superior (p = 0.02) HOMA-IR reduction (−2.5 ± 5.2, p < 0.01). The digital intervention achieved comparable results to those of the intensive obesity management program. The results suggest that Vitadio is an effective tool for supporting patients in obesity management and diabetes prevention.

MeSH

Diabetes Mellitus, Insulin Resistance, Obesity Management, Food, Obesity, Mobile Applications, Therapeutics, Metabolic Syndrome, Digital Therapeutics

Cited by

• The Use of Mobile Health Interventions for Outcomes among Middle-Aged and Elderly Patients with Prediabetes: A Systematic Review. Int J Environ Res Public Health, 2022
• Medical Telemonitoring for the Management of Hypertension in Older Patients in Japan. Int J Environ Res Public Health, 2023
• Influence of Educational Level and Healthy Habits on the Prevalence of Diabesity in a Spanish Working Population. Nutrients, 2022
• The Metaverse for Healthcare: Trends, Applications, and Future Directions of Digital Therapeutics for Urology. Int Neurourol J, 2023
• Health-promotion interventions targeting multiple behaviors: A meta-analytic review of general and behavior-specific processes of change. Psychol Bull, 2024
• Digital Therapeutics for Improving Effectiveness of Pharmaceutical Drugs and Biological Products: Preclinical and Clinical Studies Supporting Development of Drug + Digital Combination Therapies for Chronic Diseases. J Clin Med, 2024
• Assessing Discriminant Validity through Structural Equation Modeling: The Case of Eating Compulsivity. Nutrients, 2024
• Cost-effectiveness analysis of digital therapeutics for home-based cardiac rehabilitation for patients with chronic heart failure: model development and data analysis. Cost Eff Resour Alloc, 2023
• Research on disease management of chronic disease patients based on digital therapeutics: A scoping review. Digit Health, 2024
• Using Personalized Avatars as an Adjunct to an Adult Weight Loss Management Program: Randomized Controlled Feasibility Study. JMIR Form Res, 2022
• Cost-effectiveness analysis of digital therapeutics for home-based cardiac rehabilitation for patients with atrial fibrillation after catheter ablation. Digit Health, 2023
• Digital Health Interventions to Prevent Type 2 Diabetes Mellitus: Systematic Review. J Med Internet Res, 2025
• Evaluation of the Impact of Mobile Health App Vitadio in Patients With Type 2 Diabetes: Randomized Controlled Trial. J Med Internet Res, 2025
• Adoption of Digital Therapeutics in Europe. Ther Clin Risk Manag, 2025
• Effectiveness of Physical Exercise on Indicators of Metabolic Syndrome in Adults: A Systematic Review with Meta-Analysis of Clinical Trials. J Funct Morphol Kinesiol, 2025